Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Muscular Relapse in a Patient With Multiple Myeloma.

Waheed S, Zhu H, Waheed MA, Kumar M, Barlogie B.

J Clin Oncol. 2015 Dec 1;33(34):e125-9. doi: 10.1200/JCO.2013.51.6450. Epub 2014 Apr 28. No abstract available.

PMID:
24778395
2.

Clinical images: Skeletal muscle pseudo-hypertrophy in myeloma-associated amyloidosis.

Lawson TM, Bevan MA, Williams BD.

Arthritis Rheum. 2002 Aug;46(8):2251. No abstract available.

3.

Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.

Mele G, Giannotta A, Pinna S, Loseto G, Coppi MR, Brocca CM, Melpignano A, Quarta G.

Leuk Lymphoma. 2010 May;51(5):937-40. doi: 10.3109/10428191003695660. No abstract available.

PMID:
20350279
4.

[Current aspects of treatment of multiple myeloma].

Tribalto M, Avvisati G, Cantonetti M, Catalano G, Giovangrossi P, Masi M, Petrucci MT, Venditti A, Papa G.

Ann Ital Med Int. 1988 Jul-Sep;3(3):193-202. Review. Italian. No abstract available.

PMID:
3152856
5.

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome (IFM).

Blood. 2015 Feb 26;125(9):1411-7. doi: 10.1182/blood-2014-11-612069. Epub 2015 Jan 9.

6.

Panobinostat for the treatment of multiple myeloma.

Rajkumar SV.

Lancet Oncol. 2014 Oct;15(11):1178-9. doi: 10.1016/S1470-2045(14)70443-7. Epub 2014 Sep 18. No abstract available.

PMID:
25242046
7.

Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.

Kuroda J, Kobayashi T, Tsutsumi Y, Yamamoto M, Ohshiro M, Sasaki N, Shimura Y, Mizutani S, Nagoshi H, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Taniwaki M.

Int J Hematol. 2010 Nov;92(4):669-72. doi: 10.1007/s12185-010-0709-3. Epub 2010 Oct 27. No abstract available.

PMID:
20978877
8.

Histone deacetylase inhibitors in multiple myeloma.

Pratt G.

Lancet Oncol. 2013 Oct;14(11):1038-9. doi: 10.1016/S1470-2045(13)70425-X. Epub 2013 Sep 19. No abstract available.

PMID:
24055413
9.

Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.

Fouquet G, Tardy S, Demarquette H, Bonnet S, Gay J, Debarri H, Herbaux C, Guidez S, Michel J, Perrot A, Serrier C, Miljkovic D, Avet Loiseau H, Facon T, Hulin C, Leleu X.

Cancer. 2013 Oct 15;119(20):3680-6. doi: 10.1002/cncr.28274. Epub 2013 Aug 6.

10.

The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines.

Ruggeri K, Maguire Á, Cook G.

JAMA Oncol. 2016 Nov 1;2(11):1405-1406. doi: 10.1001/jamaoncol.2016.1782. No abstract available.

PMID:
27355621
11.

New hope for relapsed and refractory multiple myeloma.

Leleu X.

Lancet Oncol. 2013 Oct;14(11):1028-9. doi: 10.1016/S1470-2045(13)70399-1. Epub 2013 Sep 3. No abstract available.

PMID:
24007745
12.

Panobinostat to revert bortezomib resistance.

Moreau P.

Blood. 2013 Oct 3;122(14):2292-3. doi: 10.1182/blood-2013-08-522417. No abstract available.

13.

[Evaluation of the prognosis and response to therapy in multiple myeloma].

Venturino M, Geniram A, Guarino P, Scio P, Marini U.

Recenti Prog Med. 1984 May;75(5):451-61. Italian. No abstract available.

PMID:
6484288
14.

Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma.

Kraut EH, Young D, Farag S, James AG, Solove RJ.

Leuk Res. 2005 Oct;29(10):1233-4. Epub 2005 Apr 1. No abstract available.

PMID:
16111541
15.

Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.

Zhang Y, Liu H, Chen X, Bai Q, Liang R, Shi B, Liu L, Tian D, Liu M.

Pathol Oncol Res. 2014 Oct;20(4):987-95. doi: 10.1007/s12253-014-9785-7. Epub 2014 Jun 19.

PMID:
24942506
16.

Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.

Guglielmelli T, Bringhen S, Rrodhe S, Gay F, Cavallo F, Berruti A, Montefusco V, Piro E, Benevolo G, Petrucci MT, Caravita T, Offidani M, Corradini P, Boccadoro M, Saglio G, Palumbo A.

Eur J Cancer. 2011 Apr;47(6):814-8. doi: 10.1016/j.ejca.2010.12.026. Epub 2011 Feb 18.

PMID:
21334196
17.

"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".

Mele G, Melpignano A, Quarta G, Palumbo G, Capalbo S, Falcone A, Cascavilla N, Palazzo G, Mazza P, Iannitto E, Curci P, Rizzi R, Specchia G, Rossini B, Pavone V, Ria R, Vacca A, Buquicchio C, Tarantini G, Minoia C, Guarini A, Ditonno P, Polimeno G, Reddiconto G, Di Renzo N.

Leuk Res. 2015 Mar;39(3):279-83. doi: 10.1016/j.leukres.2014.12.007. Epub 2014 Dec 23.

PMID:
25636354
18.
19.

Bortezomib in combination with dexamethasone for relapsed multiple myeloma.

Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, Kienast J.

Leuk Res. 2005 May;29(5):587-90. Epub 2005 Jan 15.

PMID:
15755512
20.

Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.

Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez HF, Boise LH, Lee KP.

Clin Cancer Res. 2002 Dec;8(12):3658-68.

Supplemental Content

Support Center